Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

Hoshino et al., engineer a human virus receptor, hACE2, and demonstrate its potential for overcoming SARS-CoV-2 mutations that otherwise hinder therapeutic interventions. Overall, the data provide insights in to the therapeutic potential of engineered receptors.

Guardado en:

Detalles Bibliográficos
Autores principales:	Yusuke Higuchi, Tatsuya Suzuki, Takao Arimori, Nariko Ikemura, Emiko Mihara, Yuhei Kirita, Eriko Ohgitani, Osam Mazda, Daisuke Motooka, Shota Nakamura, Yusuke Sakai, Yumi Itoh, Fuminori Sugihara, Yoshiharu Matsuura, Satoaki Matoba, Toru Okamoto, Junichi Takagi, Atsushi Hoshino
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/6dacf0dd324f4db5afbaae20298e4ac1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:6dacf0dd324f4db5afbaae20298e4ac1
record_format	dspace
spelling	oai:doaj.org-article:6dacf0dd324f4db5afbaae20298e4ac12021-12-02T18:02:41ZEngineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-210.1038/s41467-021-24013-y2041-1723https://doaj.org/article/6dacf0dd324f4db5afbaae20298e4ac12021-06-01T00:00:00Zhttps://doi.org/10.1038/s41467-021-24013-yhttps://doaj.org/toc/2041-1723Hoshino et al., engineer a human virus receptor, hACE2, and demonstrate its potential for overcoming SARS-CoV-2 mutations that otherwise hinder therapeutic interventions. Overall, the data provide insights in to the therapeutic potential of engineered receptors.Yusuke HiguchiTatsuya SuzukiTakao ArimoriNariko IkemuraEmiko MiharaYuhei KiritaEriko OhgitaniOsam MazdaDaisuke MotookaShota NakamuraYusuke SakaiYumi ItohFuminori SugiharaYoshiharu MatsuuraSatoaki MatobaToru OkamotoJunichi TakagiAtsushi HoshinoNature PortfolioarticleScienceQENNature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Science Q
spellingShingle	Science Q Yusuke Higuchi Tatsuya Suzuki Takao Arimori Nariko Ikemura Emiko Mihara Yuhei Kirita Eriko Ohgitani Osam Mazda Daisuke Motooka Shota Nakamura Yusuke Sakai Yumi Itoh Fuminori Sugihara Yoshiharu Matsuura Satoaki Matoba Toru Okamoto Junichi Takagi Atsushi Hoshino Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
description	Hoshino et al., engineer a human virus receptor, hACE2, and demonstrate its potential for overcoming SARS-CoV-2 mutations that otherwise hinder therapeutic interventions. Overall, the data provide insights in to the therapeutic potential of engineered receptors.
format	article
author	Yusuke Higuchi Tatsuya Suzuki Takao Arimori Nariko Ikemura Emiko Mihara Yuhei Kirita Eriko Ohgitani Osam Mazda Daisuke Motooka Shota Nakamura Yusuke Sakai Yumi Itoh Fuminori Sugihara Yoshiharu Matsuura Satoaki Matoba Toru Okamoto Junichi Takagi Atsushi Hoshino
author_facet	Yusuke Higuchi Tatsuya Suzuki Takao Arimori Nariko Ikemura Emiko Mihara Yuhei Kirita Eriko Ohgitani Osam Mazda Daisuke Motooka Shota Nakamura Yusuke Sakai Yumi Itoh Fuminori Sugihara Yoshiharu Matsuura Satoaki Matoba Toru Okamoto Junichi Takagi Atsushi Hoshino
author_sort	Yusuke Higuchi
title	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
title_short	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
title_full	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
title_fullStr	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
title_full_unstemmed	Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2
title_sort	engineered ace2 receptor therapy overcomes mutational escape of sars-cov-2
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/6dacf0dd324f4db5afbaae20298e4ac1
work_keys_str_mv	AT yusukehiguchi engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT tatsuyasuzuki engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT takaoarimori engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT narikoikemura engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT emikomihara engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT yuheikirita engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT erikoohgitani engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT osammazda engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT daisukemotooka engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT shotanakamura engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT yusukesakai engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT yumiitoh engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT fuminorisugihara engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT yoshiharumatsuura engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT satoakimatoba engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT toruokamoto engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT junichitakagi engineeredace2receptortherapyovercomesmutationalescapeofsarscov2 AT atsushihoshino engineeredace2receptortherapyovercomesmutationalescapeofsarscov2
_version_	1718378871758258176

Engineered ACE2 receptor therapy overcomes mutational escape of SARS-CoV-2

Ejemplares similares